A column in Forbes warns that services from companies like 23andMe may be today's equivalent of snake oil. 23andMe "is marketing an expensive bit of medical technology with little proof that it will do any good," the article says. While the company has become a media darling -- thanks in large part to its Google connection -- it's touting biomarker associations that in fact "are statistically quite small, usually not enough to make any sort of prediction," the story adds.
Â